| 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | 交易日期 | 证券代码 | 证券简称 | 卖出营业部 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 平安证券股份有限 | 中信建投证券股份 | 艾力斯 | 2025-08-07 | 688578 | 80.52 | 225.46 | 2.8 | 公司济南解放路证 | 有限公司济南经四 | | Parks Arman Jald shops. III. Jury | Jack whole . I allery | | | | | | | | | 8月7日，艾力斯大宗交易成交2.8万股，成交额225.46万元，占当日总成交额的0.41%，成交价80.52元，较市场收盘价95.19元折价15.41%。 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 1.69% as of August 7, 2025, with mixed performance among constituent stocks [1] - Huada Zhizao led the gains with an increase of 4.42%, while Yuyuan Pharmaceutical and others experienced declines [1][5] - The market for the Sci-Tech Innovation Medical ETF managed by Harvest saw a turnover of 27.9% and a transaction volume of 65.88 million yuan, indicating active trading [3] Group 2 - As of August 6, 2025, the Sci-Tech Innovation Medical ETF reached a new high in scale at 237 million yuan, ranking first among comparable funds [3] - The ETF saw a net inflow of 2.96 million yuan recently, with a total of 17.65 million yuan accumulated over the last five trading days [3] - The ETF's net value increased by 49.39% over the past year, with the highest monthly return recorded at 23.29% since its inception [3] Group 3 - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading stocks including United Imaging Healthcare and BeiGene [3] - Minsheng Securities believes that domestic medical insurance policy support and overseas value recognition will sustain the ongoing trend of Chinese innovative drugs [5] - China has become a core procurement area for global trading, with traditional pharmaceutical companies accelerating their innovation and international expansion [5]

Core Insights - The report highlights the significant compensation of CFOs in the A-share market, with a total salary scale of 4.27 billion yuan and an average annual salary of 814,800 yuan for 2024 [1] - The pharmaceutical and biotechnology sector shows a higher average CFO salary of 919,700 yuan, which is 12.8% above the overall market average [1] - In Shanghai, the average CFO salary in the pharmaceutical sector reaches approximately 1,139,100 yuan, 39.8% higher than the market average, reflecting the high operational costs and talent competition in the region [1] CFO Salary Rankings - The top ten CFOs in Shanghai's pharmaceutical sector include notable figures such as Shen Bo from Shanghai Medical with a salary of 3.054 million yuan and a growth rate of 5.75% [2] - Li Yan from Ruian Gene ranks seventh with a salary of 1.573 million yuan, marking a 15.49% increase from the previous year [2][3] Company Performance - Ruian Gene reported a total revenue of 242 million yuan for 2024, a decline of 6.16% year-on-year, and a net profit of -16 million yuan, indicating a significant downturn [4] - The company's stock price fell by 48.46%, with a market capitalization of 1.03 billion yuan by the end of 2024, alongside facing compliance penalties [5] Talent Competition - The report emphasizes the strategic importance of top-tier financial executives in high-value industries, driven by the dual factors of core regional advantages and high-value industry characteristics [5]

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 | | | | 2024年医药生物行业的上海地区上市公司CFO薪酬前十 | | | | | --- | --- | --- | --- | --- | --- | --- | | 上市公司 | 行业(申万一级) | CFO | 年齡 | 学历 | 薪酬(万) | 24年总量收增长率(%) | | 上海医药 | 医药生物 | 沈波 | 53 | 硕士 | 305.4 | 5.75 | | 上海東士 | 医药生物 | 陈乐奇 | 38 | 硕士 | 292.83 | 2.67 | | 迈威生物-U | 医药生物 | 华俊 | 44 | 硕士 | 277.71 | 56.28 | | 艾力斯 | 医药生物 | 王林 | 42 | 本科 | ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index increased by 0.85%, with notable stock performances including Boryung Pharmaceutical up by 15.37% and Junshi Biosciences up by 6.49% [1] - The market activity for the Jiashi Sci-Tech Medicine ETF was robust, with a turnover rate of 18.13% and a transaction volume of 42.47 million yuan, leading in comparable funds [3] - As of August 5, the Jiashi Sci-Tech Medicine ETF achieved a net inflow of 11.73 million yuan, totaling 14.69 million yuan over the last five trading days [3] Group 2 - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading stocks including United Imaging Healthcare and Boryung Pharmaceutical [3][5] - A significant business development deal was announced by Crystal Technology Holdings, with a total order size of approximately 47 billion HKD (5.99 billion USD), marking it as one of the largest BD transactions in China's AI pharmaceutical sector for 2025 [5] - According to research from Everbright Securities, the mid-year reporting period in July may lead to positive changes in the performance of some innovative drug companies, potentially catalyzing a new market trend [6]

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 陈乐奇的履历成为焦点：中国国籍，无境外永久居留权，1987年8月出生，现年38岁，硕士学历，注册 会计师。2009年本科毕业于复旦大学管理学院财务管理专业，2019年硕士研究生毕业于中欧国际工商学 院金融工商管理专业（FMBA）。 职业经历包括普华永道中天会计师事务所资深审计师、巴德医疗科技（上海）有限公司高级财务经理、 基立福医药科技（上海）有限公司财务总监。现任郑州莱士董事、GrifolsDiagnosticSolutionsInc．董 事、同路生物董事、同方莱士医药产业投资（广东）有限公司董事、广西莱士董事、上海莱士医药有限 公司财务负责人，并于2021年10月26日起担任上海莱士财务负责人。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，新浪财经《2024年度A股CFO数据报告》正式发布，全面梳理了上市公司财务总监（CFO）的薪 酬情况。数据显示，2024年A股上市公司CFO薪酬总额达42.70亿元，平均年薪为81.48万元。 报告进一步指出，医药生物行业（申万一级）CFO薪酬 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 报告显示，2024年A股上市公司所有财务总监平均年薪为81.48万元。而395家生物医药行业上市公司 CFO平均薪酬跃升至91.97万元（中位数约74.23万元），超出全市场均值达12.8%。 聚焦上海地区，39家生物医药（申万一级）企业CFO总薪酬4442.62万元，其平均年薪进一步跃升至 113.91万元（中位数约102.20万元），较市场均值高出39.8%，显著展现区域与行业的双重溢价效应。 迈威生物CFO薪酬排名第三，个人履历显赫 在上海医药生物领域CFO前十强中，迈威生物华俊成为焦点。 根据公开信息，华俊2024年薪酬达277.71万元。需注意的是，2023年度统计的CFO薪酬159.21万元为 2023年6月上任的财务负责人华俊收入，不包括离职的叶茵薪酬。 年报显示，2024年华俊薪酬较2023年报表数据上升118.5万元，增幅74.43%。 新浪财经《2024年度A股CFO数据报告》最新披露，医药生物行业CFO薪酬显著高于A股平均水 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 新浪财经最新发布的《2024年度A股CFO数据报告》揭示了上市公司财务总监的薪酬格局。报告显示， 2024年A股上市公司CFO薪酬总额达42.70亿元，平均年薪为81.48万元。 其中，医药生物行业（申万一级）的CFO薪酬水平尤为突出，395家纳入统计的公司CFO平均年薪约为 91.97万元，显著高于全市场均值，超出幅度达12.8%。 | | | | 2024年医药生物行业的上海地区上市公司CFO薪酬前十 | | | | | --- | --- | --- | --- | --- | --- | --- | | 上市公司 | 行业(申万一级) | CFO | 年齡 | 学历 | 薪酬(万) | 24年总量收增长率(%) | | 上海医药 | 医药生物 | 沈波 | 53 | 硕士 | 305.4 | 5.75 | | 十米奥士 | 医药生物 | 陈乐奇 | 38 | 硕士 | 292.83 | 2.67 | | 迈威生物-U | 医药生物 | 华 ...

Group 1 - The core viewpoint of the report highlights the accelerated inclusion of anti-tumor drugs in the medical insurance directory, with significant effects from target coverage and volume expansion [2][10] - In 2024, 91 new drugs were added to the medical insurance directory, of which 29 were anti-tumor and immune modulators, accounting for 32% of the total [10][11] - The hospital sales revenue for anti-tumor and immune modulators reached 57.9 billion yuan, representing over half of the total sales for negotiated varieties [10][11] Group 2 - The report notes that the new anti-tumor drugs are predominantly focused on lung cancer, with 11 new drugs added for this indication, while no new drugs were included for liver, stomach, or esophageal cancers [4][23] - The current directory adjustments do not align with the cancer spectrum in China, where lung cancer accounts for 27.7% of cancer deaths, indicating unmet needs in other cancer types [4][23] Group 3 - High-priced therapies face dual challenges regarding medical insurance funds and efficacy value, particularly CAR-T therapies, which are priced significantly above the implicit payment threshold [5][27] - The report emphasizes the need for innovative payment ecosystems to support high-value therapies, as the current pricing and reimbursement models are unsustainable [28][27]

Group 1 - The core viewpoint highlights the strong performance and growth of the Kexin Pharmaceutical ETF managed by Jiashi, with significant trading activity and inflows [2] - As of August 4, the Kexin Pharmaceutical ETF Jiashi has seen a weekly average trading volume of 58.54 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 12.30 million yuan over the past two weeks, also leading among comparable funds [2] - The fund's net asset value has risen by 50.01% over the past year, placing it in the top 15.64% of index equity funds [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - The biopharmaceutical industry is expected to stabilize and grow throughout 2025, supported by favorable policies for innovative drug development and medical equipment updates [5] - The transition to the 2.0 era of innovative drugs in China is marked by a qualitative improvement, with domestic new drugs expected to participate deeply in the global market over the next decade [4]